查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2028054

癌症疫苗市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類，並預測至2026-2034年

Cancer Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

癌症疫苗市場成長要素

全球癌症疫苗市場預計在2025年達到138.6億美元，2026年成長至159.3億美元，到2034年達到629.3億美元，在預測期（2026-2034年）內複合年成長率高達18.74%。北美地區憑藉其先進的醫療基礎設施和較高的癌症發生率，引領市場，預計到2025年將佔35.97%的市場佔有率。

癌症仍然是全球重大的健康負擔，不斷上升的發病率推動了對預防性和治療性疫苗的需求。公眾意識的提高、診斷技術的進步以及免疫接種計劃的擴大，進一步促進了市場成長。

市場趨勢

影響市場格局的關鍵趨勢之一是增加對癌症預防和治療疫苗研發的投資。製藥和生物技術公司正致力於開發利用先進技術的創新疫苗，例如mRNA平台、基於人工智慧的建模和基因測序。

此外，科學研究機構與企業之間的合作正在加速創新。針對林奇症候群和惡性黑色素瘤等疾病的疫苗臨床試驗數量不斷增加，也進一步推動了市場擴張。

市場成長要素

癌症發生率增加

全球癌症負擔日益加重是市場成長的主要驅動力。子宮頸癌、肺癌、乳癌和攝護腺癌病例的不斷增加，推動了對預防性疫苗的需求成長。吸菸、污染、不健康的生活方式以及人類乳突病毒（HPV）等感染疾病等因素顯著加劇了癌症的發生率。

政府措施和免疫計劃

各國政府和國際組織正在推廣免疫接種計劃，以降低癌症發生率。公共衛生宣傳活動和人類乳突病毒(HPV)疫苗工作正在提高公眾意識並提高疫苗接種率，尤其是在開發中國家。

技術進步

個人化疫苗、新抗原標標靶化和免疫療法的創新正在改善治療效果。人工智慧與生物技術的融合正在加速高標靶性癌症疫苗的研發。

抑制因子

儘管市場呈現強勁成長勢頭，但仍存在一些限制因素。其中一個主要挑戰是個人化醫療的興起，它提供標靶治療，能夠帶來更好的治療效果。這些治療方法正在減少人們對傳統疫苗的依賴。

此外，針對特定癌症類型的核准範圍限制以及高昂的研發成本也是阻礙癌症疫苗廣泛應用的因素。

細分分析

按類型

預防領域是市場成長的主要驅動力，預計2026年將佔91.52%的市場。這主要歸功於人類乳突病毒(HPV)疫苗的廣泛應用以及人們對癌症預防日益成長的關注。由於持續的研發投入，治療領域預計將以更快的速度成長。

透過技術

重組疫苗和mRNA疫苗的進步使得分子疫苗佔最大市場佔有率（預計到2026年將達到92.27%）。載體疫苗和細胞疫苗技術也正在迅速發展。

適應症

由於HPV感染率上升和公眾意識增強，子宮頸癌細分市場佔主導地位（預計到2026年將佔88.89%）。肺癌、攝護腺癌和膀胱癌等其他細分市場預計也將穩定成長。

透過分銷管道

到2026年，醫院領域將以55.39%的市場佔有率引領市場，這主要得益於龐大的病患群體和疫苗的便捷獲取途徑。此外，由於大規模疫苗接種工作的開展，政府的供應管道也不斷擴大。

區域趨勢

北美洲

預計北美地區 2025 年的市場規模將達到 49.9 億美元，2026 年將達到 57.1 億美元。這一成長是由高癌症發生率、強大的研發生物系統以及大型企業的存在所推動的。

歐洲

預計到2025年，歐洲的疫苗研發投入將達到40.8億美元，主要得益於臨床試驗和疫苗研發領域投資的增加。德國、英國和法國等國為主要貢獻者。

亞太地區

預計到2025年，亞太地區的市場規模將達到41.2億美元，主要得益於公眾意識的提高、政府舉措的推動以及醫療基礎設施的不斷完善。中國、印度和日本等國家正引領著這一成長。

拉丁美洲、中東和非洲

預計到 2025 年，這些地區的經濟將呈現溫和成長，分別達到 3.9 億美元和 2.8 億美元，主要得益於癌症發生率的上升和醫療保健服務可近性的改善。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 主要國家癌症盛行率（2025 年）
  • 主要國家和地區監管狀況概述
  • 管道分析，主要公司
  • 產業重大發展：合併、收購與合作。
  • 新產品發布
  • 新冠疫情的影響：全球癌症疫苗市場

第5章：2021-2034年全球癌症疫苗市場分析、洞察與預測

  • 市場分析、洞察與預測：按類型
    • 預防
    • 治療方法
  • 市場分析、洞察與預測：按技術分類
    • 基於分子
    • 基於向量
    • 基於細胞
  • 市場分析、洞察與預測：按適應症分類。
    • 子宮頸癌
    • 膀胱癌
    • 攝護腺癌
    • 肺癌
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院
    • 為政府和組織提供物資
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美癌症疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲癌症疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 德國
    • 其他歐洲國家

第8章：亞太地區癌症疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲癌症疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲癌症疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Dendreon Pharmaceuticals LLC.
    • Serum Institute of India Pvt. Ltd.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Walvax Biotechnology Co., Ltd.
    • Synthaverse SA
    • Center of Molecular Immunology
    • Ferring BV
    • Wantai BioPharm
    • Dynavax Technologies Corporation
Product Code: FBI106958

Growth Factors of cancer vaccines Market

The global cancer vaccines market was valued at USD 13.86 billion in 2025 and is projected to grow to USD 15.93 billion in 2026, reaching USD 62.93 billion by 2034, registering a strong CAGR of 18.74% during the forecast period (2026-2034). North America dominated the market with a 35.97% share in 2025, supported by advanced healthcare infrastructure and high cancer prevalence.

Cancer continues to be a major global health burden, with rising incidence rates driving demand for preventive and therapeutic vaccines. Increasing awareness, improved diagnostics, and expanding immunization programs are further strengthening market growth.

Market Trends

A key trend shaping the market is the rising investment in research and development (R&D) for preventive and therapeutic cancer vaccines. Pharmaceutical and biotech companies are focusing on developing innovative vaccines using advanced technologies such as mRNA platforms, AI-based modeling, and genomic sequencing.

Additionally, collaborations between research institutes and companies are accelerating innovation. Increasing clinical trials for vaccines targeting conditions such as Lynch Syndrome and melanoma are further boosting market expansion.

Market Growth Factors

Increasing Cancer Incidence

The growing global burden of cancer is a major driver for market growth. Rising cases of cervical, lung, breast, and prostate cancers are increasing demand for preventive vaccines. Factors such as smoking, pollution, unhealthy lifestyle, and infections like HPV contribute significantly to cancer prevalence.

Government Initiatives and Immunization Programs

Governments and global organizations are promoting vaccination programs to reduce cancer incidence. Public health campaigns and HPV vaccination initiatives are improving awareness and adoption, especially in developing countries.

Technological Advancements

Innovations in personalized vaccines, neoantigen targeting, and immunotherapy are enhancing treatment outcomes. Integration of AI and biotechnology is enabling faster development of highly targeted cancer vaccines.

Restraining Factors

Despite strong growth, the market faces certain limitations. One major challenge is the rise of personalized medicine, which offers targeted therapies with better outcomes. These treatments reduce reliance on traditional vaccines.

Additionally, limited approvals for certain cancer types and high development costs also restrict widespread adoption of cancer vaccines.

Segmentation Analysis

By Type

The preventive segment dominated the market, accounting for 91.52% share in 2026, driven by increased HPV vaccine adoption and growing focus on cancer prevention. The therapeutic segment is expected to grow at a faster rate due to ongoing research and product development.

By Technology

The molecular-based segment held the largest share (92.27% in 2026) due to advancements in recombinant and mRNA vaccines. Vector-based and cell-based technologies are also gaining traction.

By Indication

The cervical cancer segment dominated the market (88.89% in 2026) due to rising HPV infections and increasing awareness. Other segments such as lung, prostate, and bladder cancer are expected to grow steadily.

By Distribution Channel

The hospital segment led the market with a 55.39% share in 2026, supported by high patient visits and better vaccine accessibility. Government supply channels are also expanding due to mass immunization initiatives.

Regional Insights

North America

North America accounted for USD 4.99 billion in 2025 and is expected to reach USD 5.71 billion in 2026. Growth is driven by high cancer incidence, strong R&D ecosystem, and presence of leading companies.

Europe

Europe held USD 4.08 billion in 2025, supported by rising investments in clinical trials and vaccine development. Countries such as Germany, the UK, and France are key contributors.

Asia Pacific

Asia Pacific reached USD 4.12 billion in 2025 and is projected to grow significantly due to increasing awareness, government initiatives, and expanding healthcare infrastructure. Countries like China, India, and Japan are leading growth.

Latin America & Middle East & Africa

These regions showed moderate growth, with USD 0.39 billion and USD 0.28 billion respectively in 2025, driven by rising cancer prevalence and improving access to healthcare services.

Competitive Landscape

The market is highly competitive with key players such as Merck & Co., Inc., GlaxoSmithKline plc, Dendreon Pharmaceuticals LLC., and Serum Institute of India Pvt. Ltd. leading innovation.

Companies are focusing on strategic collaborations, acquisitions, and clinical trials to strengthen their market position. Increasing investments in manufacturing and distribution are also supporting global expansion.

Conclusion

The cancer vaccines market is poised for significant growth, driven by rising cancer incidence, technological advancements, and increasing global focus on preventive healthcare. With strong R&D pipelines, expanding immunization programs, and innovations such as mRNA and personalized vaccines, the market is expected to transform cancer treatment and prevention. Despite challenges such as high costs and competition from personalized therapies, continuous innovation and government support will ensure sustained market expansion through 2034.

Segmentation

By Type

  • Preventive
  • Therapeutic

By Technology

  • Molecular-based
  • Vector-based
  • Cell-based

By Indication

  • Cervical Cancer
  • Bladder Cancer
  • Prostate Cancer
  • Lung Cancer
  • Others

By Distribution Channel

  • Hospitals
  • Government & Organization Supply
  • Others

By Region

  • North America (By Type, By Technology, By Indication, By Distribution Channel, By Country)
    • U.S.
    • Canada
  • Europe (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-Region)
    • France
    • Italy
    • Spain
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Different Cancers, by Key Countries, 2025
  • 4.2. Overview of Regulatory Scenario by Key Countries/Regions
  • 4.3. Pipeline Analysis, Key Players
  • 4.4. Key Industry Developments - Mergers, Acquisitions & Partnerships
  • 4.5. New Product Launches
  • 4.6. Impact of COVID-19 on Global Cancer Vaccines Market

5. Global Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Preventive
    • 5.1.2. Therapeutic
  • 5.2. Market Analysis, Insights and Forecast - By Technology
    • 5.2.1. Molecular-based
    • 5.2.2. Vector-based
    • 5.2.3. Cell-based
  • 5.3. Market Analysis, Insights and Forecast - By Indication
    • 5.3.1. Cervical Cancer
    • 5.3.2. Bladder Cancer
    • 5.3.3. Prostate Cancer
    • 5.3.4. Lung Cancer
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospitals
    • 5.4.2. Government & Organization Supply
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Preventive
    • 6.1.2. Therapeutic
  • 6.2. Market Analysis, Insights and Forecast - By Technology
    • 6.2.1. Molecular-based
    • 6.2.2. Vector-based
    • 6.2.3. Cell-based
  • 6.3. Market Analysis, Insights and Forecast - By Indication
    • 6.3.1. Cervical Cancer
    • 6.3.2. Bladder Cancer
    • 6.3.3. Prostate Cancer
    • 6.3.4. Lung Cancer
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospitals
    • 6.4.2. Government & Organization Supply
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Preventive
    • 7.1.2. Therapeutic
  • 7.2. Market Analysis, Insights and Forecast - By Technology
    • 7.2.1. Molecular-based
    • 7.2.2. Vector-based
    • 7.2.3. Cell-based
  • 7.3. Market Analysis, Insights and Forecast - By Indication
    • 7.3.1. Cervical Cancer
    • 7.3.2. Bladder Cancer
    • 7.3.3. Prostate Cancer
    • 7.3.4. Lung Cancer
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospitals
    • 7.4.2. Government & Organization Supply
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. France
    • 7.5.2. Italy
    • 7.5.3. Spain
    • 7.5.4. U.K.
    • 7.5.5. Germany
    • 7.5.6. Rest of Europe

8. Asia Pacific Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Preventive
    • 8.1.2. Therapeutic
  • 8.2. Market Analysis, Insights and Forecast - By Technology
    • 8.2.1. Molecular-based
    • 8.2.2. Vector-based
    • 8.2.3. Cell-based
  • 8.3. Market Analysis, Insights and Forecast - By Indication
    • 8.3.1. Cervical Cancer
    • 8.3.2. Bladder Cancer
    • 8.3.3. Prostate Cancer
    • 8.3.4. Lung Cancer
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospitals
    • 8.4.2. Government & Organization Supply
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Preventive
    • 9.1.2. Therapeutic
  • 9.2. Market Analysis, Insights and Forecast - By Technology
    • 9.2.1. Molecular-based
    • 9.2.2. Vector-based
    • 9.2.3. Cell-based
  • 9.3. Market Analysis, Insights and Forecast - By Indication
    • 9.3.1. Cervical Cancer
    • 9.3.2. Bladder Cancer
    • 9.3.3. Prostate Cancer
    • 9.3.4. Lung Cancer
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospitals
    • 9.4.2. Government & Organization Supply
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Preventive
    • 10.1.2. Therapeutic
  • 10.2. Market Analysis, Insights and Forecast - By Technology
    • 10.2.1. Molecular-based
    • 10.2.2. Vector-based
    • 10.2.3. Cell-based
  • 10.3. Market Analysis, Insights and Forecast - By Indication
    • 10.3.1. Cervical Cancer
    • 10.3.2. Bladder Cancer
    • 10.3.3. Prostate Cancer
    • 10.3.4. Lung Cancer
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospitals
    • 10.4.2. Government & Organization Supply
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Dendreon Pharmaceuticals LLC.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Serum Institute of India Pvt. Ltd.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. GlaxoSmithKline plc
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Walvax Biotechnology Co., Ltd.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Synthaverse S.A.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Center of Molecular Immunology
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Ferring B.V.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Wantai BioPharm
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Dynavax Technologies Corporation
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 3: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 4: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 7: North America Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 8: North America Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 9: North America Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Cancer Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 12: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 13: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 14: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 17: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 18: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 19: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 23: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 24: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 27: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 28: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 29: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cancer Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cancer Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Cancer Vaccines Market Value Share (%), by Technology, 2025 & 2034
  • Figure 4: Global Cancer Vaccines Market Value Share (%), by Indication, 2025 & 2034
  • Figure 5: Global Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Cancer Vaccines Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 8: North America Cancer Vaccines Market Value Share (%), by Type, 2025
  • Figure 9: North America Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 10: North America Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 11: North America Cancer Vaccines Market Value Share (%), by Indication, 2025
  • Figure 12: North America Cancer Vaccines Market Value Share (%), by Indication, 2025
  • Figure 13: North America Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Cancer Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Cancer Vaccines Market Value Share (%), By Country, 2025
  • Figure 17: Europe Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 18: Europe Cancer Vaccines Market Value Share (%), by Type, 2025
  • Figure 19: Europe Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 20: Europe Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 21: Europe Cancer Vaccines Market Value Share (%), by Indication, 2025
  • Figure 22: Europe Cancer Vaccines Market Value Share (%), by Indication, 2025
  • Figure 23: Europe Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 28: Asia Pacific Cancer Vaccines Market Value Share (%), by Type, 2025
  • Figure 29: Asia Pacific Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 30: Asia Pacific Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 31: Asia Pacific Cancer Vaccines Market Value Share (%), by Indication, 2025
  • Figure 32: Asia Pacific Cancer Vaccines Market Value Share (%), by Indication, 2025
  • Figure 33: Asia Pacific Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 38: Latin America Cancer Vaccines Market Value Share (%), by Type, 2025
  • Figure 39: Latin America Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 40: Latin America Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 41: Latin America Cancer Vaccines Market Value Share (%), by Indication, 2025
  • Figure 42: Latin America Cancer Vaccines Market Value Share (%), by Indication, 2025
  • Figure 43: Latin America Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 48: Middle East & Africa Cancer Vaccines Market Value Share (%), by Type, 2025
  • Figure 49: Middle East & Africa Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 50: Middle East & Africa Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 51: Middle East & Africa Cancer Vaccines Market Value Share (%), by Indication, 2025
  • Figure 52: Middle East & Africa Cancer Vaccines Market Value Share (%), by Indication, 2025
  • Figure 53: Middle East & Africa Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Cancer Vaccines Market Share (%), By Company, 2025